Purine-induced alterations of dopamine metabolism in rat pheochromocytoma PC12 cells

Brain Research Bulletin

Volumn 52, Issue 6, 2000, Pages 553-558

  Loeffler, D A ^a,b   Camp, D M ^b   Juneau, P L ^c   Harel, E ^d   LeWitt, P A ^b,e  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

^c PFIZER INC   (United States)

^d SINAI GRACE HOSPITAL   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

Author keywords

Dopamine; Parkinson's disease; PC12; Purines

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPA; GUANOSINE; HOMOVANILLIC ACID; NERVE GROWTH FACTOR; PURINE;

ANIMAL CELL; ARTICLE; BRAIN ISCHEMIA; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; NEUROMODULATION; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; PURINE METABOLISM; RAT; SECOND MESSENGER; SYNAPTIC TRANSMISSION;

ADENINE; ADENOSINE; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; GUANINE; GUANOSINE; HYPOXANTHINE; NEOSTRIATUM; NEURAL PATHWAYS; NEURONS; PARKINSON DISEASE; PC12 CELLS; PURINES; RATS; SUBSTANTIA NIGRA; URIC ACID; XANTHINE;

EID: 0033847190     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(00)00293-8     Document Type: Article

References (43)

1. Alexander, S. P.; Reddington, M. The cellular localization of adenosine receptors in rat neostriatum. Neuroscience 28:645-651; 1989.
2. Allsop, J.; Watts, R. W. Purine synthesis and salvage in brain and liver. Adv. Exp. Med. Biol. 165(part B):21-26; 1984.
3. Baker, P. F. Intracellular signalling, GTP and calcium release. Nature 320:395; 1986.
4. Beal, M. F.; Matson, W. R.; Storey, E.; Milbury, P.; Ryan, E. A.; Ogawa, T.; Bird, E. D. Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex. J. Neurol. Sci. 108:80-87; 1992.
5. Chern, Y.; Lai, H.-L.; Fong, J. C.; Liang, Y. Multiple mechanisms for desensitization of A2a adenosine receptor-mediated cAMP elevation in rat pheochromocytoma PC12 cells. Mol. Pharmacol. 44:950-958; 1993.
6. Chowdhury, M.; Fillenz, M. Presynaptic adenosine A2 and N-methylD-aspartate receptors regulate dopamine synthesis in rat striatal synaptosomes. J. Neurochem. 56:1783-1788; 1991.
7. Degrell, I.; Niklasson, F. Purine metabolites in the CSF in presenile and senile dementia of Alzheimer type, and in multi-infarct dementia. Arch. Gerontol. Geriatr. 7:173-178; 1988.
8. Ferre, S.; Fredholm, B. B.; Morelli, M.; Popoli, P.; Fuxe, K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20:482-487; 1997.
9. 1 receptors in stably cotransfected fibroblast cells. J. Biol. Chem. 273:4718-4724; 1998.
10. Fredholm, B. B.; Arslan, G.; Johansson, B.; Kuli, B.; Svenningsson, P. Adenosine A2A receptors and the actions of caffeine. In: Okada, Y., ed. The role of adenosine in the nervous system. Amsterdam: Elsevier; 1997:51-74.
11. Greene, L. A.; Tischler, A. S. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc. Natl. Acad. Sci. USA 73:2424-2428; 1976.
12. Greene, L. A.; Tischler, A. S. PC12 pheochromocytoma cultures in neurobiological research. Adv. Cell. Neurobiol. 3:373-414; 1982.
13. Griffith, M.; Jarvis, S. M. Nucleoside and nucleobase transport systems in mammalian cells. Biochem. Biophys. Acta 1286:153-181; 1996.
14. Gysbers, J. W.; Rathbone, M. P. Guanosine enhances NGF-stimulated neurite outgrowth in PC12 cells. Neuroreport 3:997-1000; 1992.
15. Gysbers, J. W.; Rathbone, M. P. GTP and guanosine synergistically enhance NGF-induced neurite outgrowth from PC12 cells. Int. J. Dev. Neurosci. 14:19-34; 1996.
16. Harms, H. H.; Wardeh, G.; Mulder, A. H. Effects of adenosine on depolarization-induced release of various radiolabeled neurotransmitters from slices of rat corpus striatum. Neuropharmacology 18:577-580; 1979.
17. Hide, I.; Padgett, W.; Jacobson, K. A.; Daly, J. W. A2a adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: Characterization with radioligand binding and by activation of adenylate cyclase. Mol. Pharmacol. 41:352-359; 1992.
18. Hochberg, Y.; Tamhane, A. C. Multiple comparison procedures. Toronto: John Wiley & Sons; 1987:181-193.
19. Hornykiewicz, O.; Kish, S. J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45:19-34; 1986.
20. Jin, S.; Johansson, B.; Fredholm, B. B. Effects of adenosine Al and A2 receptor activation on electrically evoked dopamine and acetylcholine release from rat striatal slices. J. Pharmacol. Exp. Ther. 267:801-808; 1993.
21. Lazzarino, G.; Vagnozzi, R.; Tavazzi, B.; Pastore, F. S.; Di Pierro, D.; Siragusa, P.; Belli, A.; Guiffre, R.; Giardina, B. MDA, oxypurines, and nucleosides relate to reperfusion in short-term incomplete cerebral ischemia in the rat. Free Radic. Biol. Med. 13:489-498; 1992.
22. LeWitt, P.; Galloway, M.; Matson, W.; Milbury, P.; McDermott, M.; Oakes, D.; Shoulson, I. CSF studies in unmedicaled Parkinson disease: Dopamine melabolism and xanlhine. Soc. Neurosci. Abst. 18:1248; 1992.
23. Lillrank, S. M.; Lipska, B. K.; Weinberger, D. R.; Fredholm, B. B.; Fuxe, K.; Ferre, S. Adenosine and dopamine receptor antagonist binding in the rat ventral and dorsal striatum: Lack of changes after a neonatal bilateral lesion of the ventral hippocampus. Neurochem. Int. 34:235-244; 1999.
24. Loeffler, D. A.; LeWitt, P. A.; Juneau, P. L.; Camp, D. M.; DeMaggio, A. J.; Milbury, P.; Matson, W. R.; Rathbone, M. P. Altered guanosine and guanine concentrations in rabbit striatum following increased dopamine turnover. Brain Res. Bull. 45:297-299; 1998.
25. Michaelis, M. L.; Michaelis, E. K.; Myers, S. L. Adenosine modulation of synaptosomal dopamine release. Life Sci. 24:2083-2092; 1979.
26. Morimoto, K.; Shimizu, H.; Hayakawa, T.; Shimada, N.; Nil, Y.; Masana, Y.; Kato, A.; Mogami, H. Purine catabolites in cerebral interstitial fluid during progression of and recovery from ischemia. Neurol. Med. Chir. (Tokyo) 31:129-134; 1991.
27. Myers, S.; Pugsley, T. A. Decrease in rat striatal dopamine synthesis and metabolism in vivo by metabolically stable adenosine receptor antagonists. Brain Res. 375:193-197; 1986.
28. Niklasson, F.; Agren, H.; Hallgren, R. Purine and monoamine metabolites in cerebrospinal fluid: Parallel purinergic and monoaminergic activation in depressive illness? J. Neurol. Neurosurg. Psychiatry 46:255-260; 1983.
29. Nonaka, H.; Ichimura, M.; Takeda, M.; Nonaka, Y.; Shimada, J.; Suzuki, F.; Yamaguchi, K.; Kase, H. KF17837 ((E)-8-3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine), a potent and selective adenosine A2 receptor antagonist. Fur. J. Pharmacol. 267:335-341; 1994.
30. Onali, P.; Olianas, M. C.; Bunse, B. Evidence that adenosine A2 and dopamine autoceptors antagonistically regulate tyrosine hydroxylase activity in rat striatal synaptosomes. Brain Res. 456:302-309; 1988.
31. O'Neill, R. D. Adenosine modulation of striatal neurotransmitter release monitored in vivo using voltametry. Neurosci. Lett. 63:11-16; 1986.
32. Ongini, E.; Fredholm, B. B. Pharmacology of adenosine A2A receptors. Trends Pharmacol. Sci. 17:364-372; 1996.
33. Pothos, E.; Desmond, M.; Sulzer, D. L-3,4-dihydroxyphenylalanine increases the quantal size of exocytotic dopamine release in vitro. J. Neurochem. 66:629-636; 1996.
34. Presse, F.; Cardona, B.; Borsu, L.; Nahon, J. L. Lithium increases melanin-concentrating hormone mRNA stability and inhibits tyrosine hydroxylase gene expression in PC12 cells. Brain Res. Mol. Brain Res. 52:270-283; 1997.
35. Ribeiro, J. A. Adenosine A2A receptor interactions with receptors for other neurotransmitters and neuromodulators. Eur. J. Pharmacol. 375: 101-113; 1999.
36. Richardson, P. J.; Kase, H.; Jenner, P. G. Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol. Sci. 18:338-344; 1997.
37. Robinson, T. E.; Camp, D. M. The feasibility of repeated microdialysis for within-subjects design experiments: Studies on the mesostriatal dopamine system. In: Robinson, T. E.; Justice, J. B., eds. Microdialysis in the neurosciences. Amsterdam: Elsevier; 1991:189-234.
38. Stryer, L. Biochemistry, 2nd ed. New York: W. H. Freeman and Co.; 1991:240.
39. Tohgi, H.; Abe, T.; Takahashi, S.; Kikuchi, T. The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson's disease. J. Neural Transm. Park. Dis. Dement. Sect. 6:119-126; 1993.
40. Uemura, Y.; Miller, J. M.; Matson, W. R.; Beal, M. F. Neurochemical analysis of focal ischemia in rats. Stroke 22:1548-1553; 1991.
41. Wei, Q.; Jurma, O. P.; Andersen, J. K. Increased expression of monoamine oxidase-B resulls in enhanced neurile degeneration in melhamphelamine-treated PC12 cells. J. Neurosci. Res. 50:618-626; 1997.
42. Williams, M. Purine nucleosides and nucleotides as central nervous system modulators. Ann. N.Y. Acad. Sci. 603:93-107; 1990.
43. Wojcek, W. J.; Neff, N. H. Differential location of A1 and A2 receptors in the striatum. Neurosci. Lett. 41:55-60; 1983.